{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:07:41Z","timestamp":1783908461597,"version":"3.55.0"},"reference-count":16,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"DOI":"10.2478\/prilozi-2019-0024","type":"journal-article","created":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T05:31:08Z","timestamp":1570858268000},"page":"133-134","source":"Crossref","is-referenced-by-count":0,"title":["Could Serum Sclerostin Help in Early Assessment and Treatment of Chronic Kidney Disease \u2013 Mineral and Bone Disorder?"],"prefix":"10.2478","volume":"40","author":[{"given":"Andreja","family":"Figurek","sequence":"first","affiliation":[{"name":"Medical faculty , University of Banja Luka , Banja Luka , Republic of Srpska, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merita","family":"Rroji","sequence":"additional","affiliation":[{"name":"Department of Nephrology , University Hospital Center \u201cMother Tereza\u201d , Tirana , Albania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goce","family":"Spasovski","sequence":"additional","affiliation":[{"name":"University Department of Nephrology, Medical Faculty , University of Skopje , Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"key":"2026071212100024999_j_prilozi-2019-0024_ref_001_w2aab3b7c16b1b6b1ab1ab1Aa","doi-asserted-by":"crossref","unstructured":"1. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease \u2013 a systematic review and meta-analysis. PloS One 2016; 11(7): e0158765.10.1371\/journal.pone.0158765493490527383068","DOI":"10.1371\/journal.pone.0158765"},{"key":"2026071212100024999_j_prilozi-2019-0024_ref_002_w2aab3b7c16b1b6b1ab1ab2Aa","doi-asserted-by":"crossref","unstructured":"2. Hruska KA, Sugatani T, Agapova O, et al. The chronic kidney disease \u2013 mineral and bone disorder (CKD-MBD): Advances in pathophysiology. Bone 2017; 100: 80\u201386.10.1016\/j.bone.2017.01.02328119179550271628119179","DOI":"10.1016\/j.bone.2017.01.023"},{"key":"2026071212100024999_j_prilozi-2019-0024_ref_003_w2aab3b7c16b1b6b1ab1ab3Aa","doi-asserted-by":"crossref","unstructured":"3. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003; 22: 6267\u20136276.10.1093\/emboj\/cdg5991463398629184014633986","DOI":"10.1093\/emboj\/cdg599"},{"key":"2026071212100024999_j_prilozi-2019-0024_ref_004_w2aab3b7c16b1b6b1ab1ab4Aa","doi-asserted-by":"crossref","unstructured":"4. Figurek A, Spasovski G. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder? Int Urol Nephrol 2018; 50(10): 1863\u20131870.3003067710.1007\/s11255-018-1935-530030677","DOI":"10.1007\/s11255-018-1935-5"},{"key":"2026071212100024999_j_prilozi-2019-0024_ref_005_w2aab3b7c16b1b6b1ab1ab5Aa","doi-asserted-by":"crossref","unstructured":"5. Cejka D, Marculescu R, Kozakowski N, et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 2014; 99: 248\u2013255.10.1210\/jc.2013-278624187403","DOI":"10.1210\/jc.2013-2786"},{"key":"2026071212100024999_j_prilozi-2019-0024_ref_006_w2aab3b7c16b1b6b1ab1ab6Aa","doi-asserted-by":"crossref","unstructured":"6. Sabbagh Y, Graciolli FG, O\u2019Brien S, et al. Repression of osteocyte Wnt\/-catenin signaling is an early event in the progression of renal osteodystrophy. J. Bone. Miner. Res. 2012; 27: 1757\u2013177210.1002\/jbmr.163022492547","DOI":"10.1002\/jbmr.1630"},{"key":"2026071212100024999_j_prilozi-2019-0024_ref_007_w2aab3b7c16b1b6b1ab1ab7Aa","doi-asserted-by":"crossref","unstructured":"7. Bielesz BO, Hempfing T, Kieweg H, et al. Sclerostin declines during hemodialysis and appears in Dialysate. Blood Purif 2014; 38: 30\u201336.10.1159\/00036499225228355","DOI":"10.1159\/000364992"},{"key":"2026071212100024999_j_prilozi-2019-0024_ref_008_w2aab3b7c16b1b6b1ab1ab8Aa","doi-asserted-by":"crossref","unstructured":"8. Yamada S, Tsuruya K, Tokumoto M, et al. Factors associated with serum soluble inhibitors of Wnt-\u03b2-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis. Nephrology (Carlton) 2015; 20: 639\u2013645.10.1111\/nep.1250925974190","DOI":"10.1111\/nep.12509"},{"key":"2026071212100024999_j_prilozi-2019-0024_ref_009_w2aab3b7c16b1b6b1ab1ab9Aa","unstructured":"9. Desjardins L, Liabeuf S, Oliveira R.B, et al. Uremic toxicity and sclerostin in chronic kidney disease patients. J Clin Endocrinol Metab 2014; 99: E1854-61."},{"key":"2026071212100024999_j_prilozi-2019-0024_ref_010_w2aab3b7c16b1b6b1ab1ac10Aa","doi-asserted-by":"crossref","unstructured":"10. Satoa M, Hanafusab N, Kawaguchia H, et al. A Prospective Cohort Study Showing No Association Between Serum Sclerostin Level and Mortality in Maintenance Hemodialysis Patients. Kidney Blood Press Res 2018; 43: 1023\u2013103310.1159\/00049082429940587","DOI":"10.1159\/000490824"},{"key":"2026071212100024999_j_prilozi-2019-0024_ref_011_w2aab3b7c16b1b6b1ab1ac11Aa","doi-asserted-by":"crossref","unstructured":"11. Carvalho Goncalves FL, Elias RM, dos Reis L.M, et al. Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrology 2014; 15: 190.10.1186\/1471-2369-15-190426542225465028","DOI":"10.1186\/1471-2369-15-190"},{"key":"2026071212100024999_j_prilozi-2019-0024_ref_012_w2aab3b7c16b1b6b1ab1ac12Aa","doi-asserted-by":"crossref","unstructured":"12. Drechsler C, Evenepoel P, Vervloet MG, et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2015; 30: 288\u2013293.10.1093\/ndt\/gfu30125248363","DOI":"10.1093\/ndt\/gfu301"},{"key":"2026071212100024999_j_prilozi-2019-0024_ref_013_w2aab3b7c16b1b6b1ab1ac13Aa","doi-asserted-by":"crossref","unstructured":"13. Nowak A, Artunc F, Serra AL, et al. Sclerostin quo vadis ? \u2013 Is this a useful long-term mortality parameter in prevalent hemodialysis patients? Kidney Blood Press Res 2015; 40: 266\u2013276.10.1159\/000368502","DOI":"10.1159\/000368502"},{"key":"2026071212100024999_j_prilozi-2019-0024_ref_014_w2aab3b7c16b1b6b1ab1ac14Aa","doi-asserted-by":"crossref","unstructured":"14. Sooling ASK, Harslof T, Langdahl B. The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis 2018; 10(5-6): 105\u2013115.10.1177\/1759720X18775936600909429942362","DOI":"10.1177\/1759720X18775936"},{"key":"2026071212100024999_j_prilozi-2019-0024_ref_015_w2aab3b7c16b1b6b1ab1ac15Aa","doi-asserted-by":"crossref","unstructured":"15. Brandenburg VM, Verhulst A, Babler A, et al. Sclerostin in chronic kidney disease \u2013 mineral and bone disorder think before you block it! Nephrol Dial Transplant 2018 May 24. doi: 10.1093\/ndt\/gfy129.10.1093\/ndt\/gfy12929846712","DOI":"10.1093\/ndt\/gfy129"},{"key":"2026071212100024999_j_prilozi-2019-0024_ref_016_w2aab3b7c16b1b6b1ab1ac16Aa","unstructured":"16. Xue-Li Du, Wen-Bo Li, and Bo-Jie Hu. (2018) Application of artificial intelligence in ophthalmology. Int J Ophthalmol 11(9): 1555\u20131561."}],"container-title":["PRILOZI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/prilozi\/40\/2\/article-p133.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/prilozi-2019-0024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:29:58Z","timestamp":1783906198000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/prilozi-2019-0024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,10,11]]},"published-print":{"date-parts":[[2019,10,1]]}},"alternative-id":["10.2478\/prilozi-2019-0024"],"URL":"https:\/\/doi.org\/10.2478\/prilozi-2019-0024","relation":{},"ISSN":["1857-8985","1857-9345"],"issn-type":[{"value":"1857-8985","type":"electronic"},{"value":"1857-9345","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,1]]}}}